No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Xyntha Solofuse is a hematological drug used to treat hemophilia A, a genetic disorder that impairs the body's ability to form blood clots. Xyntha Solofuse is a recombinant factor VIII (rFVIII) therapy, which is a type of protein replacement therapy. It is administered via a single-use, pre-filled syringe, and is designed to provide a more convenient and efficient treatment option for patients with hemophilia A.
Xyntha Solofuse is a relatively new product in the hematological drug market, and is currently the only single-use, pre-filled syringe available for the treatment of hemophilia A. It is designed to provide a more convenient and efficient treatment option for patients, and has been well-received by the medical community.
Some companies in the Xyntha Solofuse market include Pfizer, Inc., Biogen, Inc., and Shire plc. Show Less Read more
